Johnson & Johnson (NYSE:JNJ) Stock Position Increased by Allegheny Financial Group LTD

Allegheny Financial Group LTD increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.8% during the third quarter, Holdings Channel.com reports. The fund owned 13,170 shares of the company’s stock after acquiring an additional 109 shares during the quarter. Johnson & Johnson accounts for approximately 1.0% of Allegheny Financial Group LTD’s investment portfolio, making the stock its 21st largest position. Allegheny Financial Group LTD’s holdings in Johnson & Johnson were worth $2,151,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Price T Rowe Associates Inc. MD boosted its stake in shares of Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. FMR LLC boosted its position in shares of Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Johnson & Johnson by 0.3% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after buying an additional 24,505 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Down 0.5 %

Shares of Johnson & Johnson stock opened at $168.74 on Monday. The stock has a 50-day simple moving average of $176.14 and a 200-day simple moving average of $171.20. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The firm has a market cap of $441.17 billion, a price-to-earnings ratio of 23.50, a P/E/G ratio of 3.19 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 62.95%.

Insider Activity

In related news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several analyst reports. Atlantic Securities dropped their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price on the stock. Bank of America decreased their target price on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a research report on Friday, October 14th. Sanford C. Bernstein dropped their price target on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.